Ultragenyx Pharmaceutical Inc.
DE ˙ DB ˙ US90400D1081
€ 19,00 ↓ -0.11 (-0.60%)
2026-06-05
PREÇO DA AÇÃO
SecurityDE:UP0 / Ultragenyx Pharmaceutical Inc.
InstitutionPinnacle Associates Ltd
Latest Disclosed Ownership102,710 shares
Latest Disclosed Value $ 2,151,775
Pinnacle Associates Ltd reports 7.93% decrease in ownership of UP0 / Ultragenyx Pharmaceutical Inc.

On April 21, 2026 - Pinnacle Associates Ltd filed a 13F-HR form disclosing ownership of 102,710 shares of Ultragenyx Pharmaceutical Inc. (DE:UP0) valued at $1,735,799 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 111,560 shares of Ultragenyx Pharmaceutical Inc.. This represents a change in shares of -7.93% during the quarter. The current value of the position is $1,951,490 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-21 2026-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 102,710 -8,850 -7.93 2,152 -16.14 0.0276
2026-02-05 2025-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 111,560 -3,285 -2.86 2,566 -25.74 0.0329
2025-11-13 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 114,845 577 0.50 3,455 -16.85 0.0458
2025-08-04 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 114,268 -29,107 -20.30 4,155 -19.98 0.0602
2025-05-06 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 143,375 -5,118 -3.45 5,192 -16.90 0.0761
2025-02-14 2024-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 148,493 29,133 24.41 6,247 9.46 0.0848
2024-10-25 2024-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 119,360 -41,660 -25.87 5,708 -13.75 0.0971
2024-07-30 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 161,020 41,633 34.87 6,618 18.71 0.1036
2024-04-26 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 119,387 27 0.02 5,574 -2.33 0.0879
2024-01-19 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 119,360 5 0.00 5,708 34.12 0.0960
2023-10-24 2023-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 119,355 -3,841 -3.12 4,255 -25.13 0.0791
2023-07-27 2023-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 123,196 -3,201 -2.53 5,683 12.13 0.0986
2023-05-05 2023-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 126,397 -2,039 -1.59 5,069 -14.82 0.1037
2023-02-01 2022-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 128,436 -1,982 -1.52 5,950 10.16 0.1297
2023-01-25 2022-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 127,623 -2,795 4,559 0.0001
2022-11-01 2022-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 130,418 -3,640 -2.72 5,401 -32.47 0.1240
2022-08-02 2022-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 134,058 -2,221 -1.63 7,998 -19.19 0.1744
2022-05-05 2022-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 136,279 -5,295 -3.74 9,897 -16.87 0.1752
2022-02-02 2021-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 141,574 -782 -0.55 11,905 -7.27 0.2054
2021-10-19 2021-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 142,356 -4,159 -2.84 12,839 -8.10 0.2367
2021-08-02 2021-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 146,515 1,225 0.84 13,970 -15.55 0.2526
2021-05-12 2021-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 145,290 -13,065 -8.25 16,543 -24.53 0.3155
2021-01-26 2020-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 158,355 -9,331 -5.56 21,921 59.06 0.4451
2020-10-23 2020-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 167,686 -6,513 -3.74 13,782 1.14 0.3273
2020-08-14 2020-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 174,199 -4,572 -2.56 13,626 71.55 0.3360
2020-05-13 2020-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 178,771 -33,616 -15.83 7,943 -12.44 0.2413
2020-02-03 2019-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 212,387 139,380 190.91 9,071 190.46 0.1986
2019-11-08 2019-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 73,007 73,007 3,123 0.0736
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.